A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations

J Med Genet. 2010 Nov;47(11):771-4. doi: 10.1136/jmg.2010.078113. Epub 2010 Aug 30.

Abstract

Introduction: The Li-Fraumeni Syndrome is caused by a germline TP53 mutation and is associated with a high risk of breast cancer at young ages. Basal (triple negative) breast cancers are now well recognised to be a typical sub-type of breast cancer developing in a large proportion of BRCA1 gene carriers. We considered whether a similar narrow sub-type of breast cancer was found in TP53 gene mutation carriers.

Objective: A hypothesis generating study to investigate whether there are specific breast tumour characteristics associated with germline TP53 mutations.

Methods: Pathological characteristics in 12 breast cancers arising in nine patients carrying pathogenic TP53 mutations were compared to a reference panel of 231 young onset breast tumours included in the POSH study.

Results: Patients carrying a TP53 mutation showed a significantly higher likelihood of developing a breast cancer with Human Epidermal growth factor Receptor (HER2) amplification (83%) when compared to the cohort of young onset breast cancer cases (16%); ER and PR status were equivalent between groups.

Conclusion: These findings suggest that breast cancer developing on a background of an inherited TP53 mutation is highly likely to present with amplification of HER2.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Breast Neoplasms / genetics*
  • Breast Neoplasms / metabolism
  • Breast Neoplasms / pathology
  • DNA Mutational Analysis
  • Female
  • Gene Amplification
  • Germ-Line Mutation*
  • Humans
  • Immunohistochemistry
  • In Situ Hybridization
  • Li-Fraumeni Syndrome / genetics
  • Receptor, ErbB-2 / genetics*
  • Receptor, ErbB-2 / metabolism
  • Tumor Suppressor Protein p53 / genetics*
  • Tumor Suppressor Protein p53 / metabolism
  • Young Adult

Substances

  • Tumor Suppressor Protein p53
  • Receptor, ErbB-2